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Cocaine’s behavioral-stimulant effects derive from
potentiation of synaptic signaling by dopamine and
serotonin leading to transcriptional alterations in
postsynaptic cells. We report that a signaling cas-
cade involving nitric oxide (NO) and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) medi-
ates cocaine’s transcriptional and behavioral
actions. Lower, behavioral-stimulant doses enhance
the cAMP response element-binding (CREB) sig-
naling system, while higher, neurotoxic doses stimu-
late the p53 cytotoxic system. The drug CGP3466B,
which potently and selectively blocks GAPDH nitro-
sylation and GAPDH-Siah binding, prevents these
actions as well as behavioral effects of cocaine
providing a strategy for anticocaine therapy.
INTRODUCTION
Behavioral-stimulant effects of cocaine are thought to be initi-
ated by potentiation of the synaptic actions of dopamine and,
possibly, serotonin associated with inhibition of neurotransmitter
transport (Amara and Kuhar, 1993; Amara and Sonders, 1998;
Thomas et al., 2008). Nuclear events triggered by cocaine,
including chromatin remodeling (Levine et al., 2011; Maze
et al., 2010; Taniguchi et al., 2012), have been linked to behav-
ioral actions with reports of increased signaling via transcription
factors such as CREB and DfosB (McClung and Nestler, 2003;
Robison and Nestler, 2011) leading to augmented expression
of transcriptional targets such as BDNF (Graham et al., 2007;
Im et al., 2010; McGinty et al., 2010) and immediate-early genes
such as c-fos and Arc (Larson et al., 2010). Mechanisms con-
necting neurotransmitter-receptor interactions to these tran-
scriptional systems upon cocaine treatment have not been well
characterized.
A signaling system initiated by nitric oxide (NO) mediates
diverse physiologic and pathophysiologic events in blood ves-
sels, inflammatory tissues, and in neuronal systems with notable
behavioral alterations attendant upon deletion of neuronal NOsynthase (nNOS) (Tricoire and Vitalis, 2012; Zhou and Zhu,
2009). The cascade commences with activation of NO-elicited
nitrosylation of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) with nuclear translocation of GAPDH, together with
the ubiquitin E3 ligase Siah1. With cytotoxic stresses nuclear
GAPDH activates the histone acetylating enzymes p300/CBP
leading to acetylation and activation of p53 and enhancement
of cell death transcriptional targets such as PUMA and Bax
(Sen et al., 2008; Zhou and Zhu, 2009). With physiologic stimuli,
such as the neurotrophic factors BDNF (brain-derived neurotro-
phic factor) and NGF (nerve growth factor), the nuclear complex
of nitrosylated GAPDH, linked to Siah1 and the histone-methyl-
ating enzyme SUV39H1, triggers degradation of SUV39H1 via
the ubiquitin E3 ligase activity of Siah1 (Sen and Snyder, 2011).
This facilitates acetylation of histone H3 leading to CREB binding
to DNA with enhanced expression of CREB-regulated genes
such as c-fos and BDNF and associated augmentation of nerve
outgrowth.
In the present study, we report a signaling cascade wherein
low, behavioral-stimulant doses of cocaine trigger formation of
the nitrosylated GAPDH/Siah1 complex leading to augmented
expression of CREB genes, whereas higher, neurotoxic doses
activate the NO/GAPDH/p53 system. CGP3466B, a very potent
inhibitor of GAPDH nitrosylation and GAPDH-Siah binding, pre-
vents both stimulant and neurotoxic actions of cocaine.
RESULTS
Nitrosylated GAPDH Contributes to Both Behavioral and
Neurotoxic Effects of Cocaine
To determine a role for the NO-GAPDH cascade in cocaine
actions, we treated mice with single behavioral-stimulant doses
of cocaine (5–30 mg/kg; Figure 1A) or a neurotoxic regimen of 5
doses of cocaine (30–50 mg/kg), monitoring nitrosylation (Fig-
ure 1B) of GAPDH (SNO-GAPDH) in mice with targeted deletion
of nNOS. Both stimulant and neurotoxic treatment protocols of
cocaine augment levels of nitrosylated GAPDH, with the neuro-
toxic protocol eliciting a larger effect. All these influences of
cocaine are virtually abolished in nNOS knockout mice, estab-
lishing that cocaine impacts this signaling pathway.
To discriminate effects of dose and dosing scheduled, we
administered single 5–40 mg/kg doses as well as multipleNeuron 78, 623–630, May 22, 2013 ª2013 Elsevier Inc. 623
Wt nN
OS
 KO
Wt nN
OS
 KO
Wt nN
OS
 KO
Wt nN
OS
 KO
c-fos
Arc
Cocaine
mg/kg5 15 30
- - + + + + + +
Wt nN
OS
 KO
Wt nN
OS
 KO
Wt nN
OS
 KO
Wt nN
OS
 KO
PUMA
Bax
Cocaine
mg/kg30 40 50
- - + + + + + +
Cocaine
mg/kg30 40 50
- - + + + + + +
Actin Actin
c-fosPUMA
SNO GAPDH
GAPDHInput
Cocaine
mg/kg5 15 30
- - + + + + + +
SNO GAPDH
GAPDHInput
Input
Wt nN
OS
 KO
Wt nN
OS
 KO
Wt nN
OS
 KO
Wt nN
OS
 KO
Wt nN
OS
 KO
Wt nN
OS
 KO
Wt nN
OS
 KO
Wt nN
OS
 KO
1
2
3
Cocaine
mg/kg5
- - + +
15
+ +
30
+ +
4
C
R
EB
 b
in
di
ng
 to
 c
-fo
s 
pr
om
ot
er
1
2
3
Cocaine
mg/kg30
- - + +
40
+ +
50
+ +
4
p5
3 
bi
nd
in
g 
to
 P
U
M
A 
pr
om
ot
er
nNOS KO
Wt
* *
**
*
**
A B
C D
E F
Input
Striatum
Striatum
Striatum
Striatum
Striatum Striatum
Figure 1. Neuronal NO Mediates Cocaine’s
Enhancement of p53 and CREB Gene Tran-
scription
(A and B) Levels of nitrosylated GAPDH (SNO-
GAPDH) in mice receiving behavioral-stimulant
doses (A) or neurotoxic doses (B) of cocaine in
both wild-type and nNOS knockout (nNOS KO)
mice. (C and D) Differential expression of c-fos,
BDNF, Arc, PUMA, and Bax proteins with behav-
ioral doses (C) or neurotoxic doses (D) of cocaine.
(E and F) Quantitative ChIP analysis of binding of
CREB and p53 to c-fos and PUMA promoters in
striatum following cocaine treatment. Data were
normalized by total input and presented as bound/
input. *p < 0.01, n = 3, one-way ANOVA, mean ±
SEM. See also Figure S1.
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SNO-GAPDH Is Key to Cocaine Behaviortreatments with these doses. Single doses of cocaine (5–
30 mg/kg) induce CREB binding to the c-fos promoter (see Fig-
ure S1A available online) with increases in c-fos protein levels
(Figure S1B). By contrast, treatment with 40 mg/kg cocaine,
either in single or multiple doses, induces p53 binding to the
PUMA promoter (Figure S1C), with attendant increases in
PUMA protein levels (Figure S1B). Administering 30 mg/kg
cocaine for 5 days induces PUMA (Figure S1B, red dotted
box), while single doses of 30 mg/kg cocaine induce c-fos level
(Figure S1B, blue dotted box). Accordingly, single doses
of cocaine (5–30 mg/kg) were used to study behavioral effects
of cocaine and 40 mg/kg cocaine was employed as a neurotoxic
dose. Mice receiving 30 mg/kg cocaine for 5 consecutive days
were also used to study cocaine-associated cell death.
Earlier, we reported that NO-GAPDH signaling initiates a
cascade leading to nuclear transcription of p53 and CREB
targets (Sen et al., 2008; Sen and Snyder, 2011). The stimulant
cocaine regimen augments levels of c-fos and the immediate-
early gene Arc but not PUMA, and these effects are lost in
nNOS knockout mice (Figure 1C). By contrast, the neurotoxic
cocaine regimen enhances levels of PUMA and Bax but not
c-fos with these actions absent in nNOS mutants (Figure 1D).
Utilizing ChIP assays, wemonitored CREB binding to the c-fos
promoter with stimulant doses of cocaine (Figure 1E) and p53
binding to the PUMA promoter with the neurotoxic regimen (Fig-
ure 1F). CREB-c-fos promoter binding is markedly increased by624 Neuron 78, 623–630, May 22, 2013 ª2013 Elsevier Inc.stimulant doses of cocaine, effects abol-
ished in nNOS knockouts (Figure 1E).
The neurotoxic cocaine regimen greatly
increases p53 binding to the PUMA pro-
moter, effects which are lost in nNOS
knockouts (Figure 1F).
Nitrosylation of GAPDH Is Required
for Cocaine Actions In Vivo
Loss of cocaine actions in nNOS
knockout mice establishes a role for
neuronal NO under these influences. To
assess more directly whether effects of
cocaine are specifically mediated by
GAPDH nitrosylation, we administeredlentiviral particles of wild-type GAPDH and C150S mutant of
GAPDH—which cannot be nitrosylated—into the striatum of
mice brain. Expression levels of both constructs are the same
(Figures 2A and 2B). After overexpression of these constructs,
we treated mice with single behavioral-stimulant doses of
cocaine (5–30 mg/kg) or a neurotoxic regimen of 5 doses of
cocaine (30–50 mg/kg) and monitored nitrosylation of GAPDH.
Nitrosylation of wild-type but not C150S mutant GAPDH is
observed after treatment with both behavioral and neurotoxic
doses of cocaine (Figures 2C and 2D). As expected, CREB bind-
ing to the c-fos promoter and levels of c-fos are increased in
mice overexpressing wild-type GAPDH but not GAPDH C150S
(Figures 2E and 2F). Similarly, with neurotoxic doses of cocaine,
p53 binding to the PUMA promoter and PUMA protein levels are
enhanced in mice overexpressing wild-type GAPDH (Figures 2G
and 2H). This suggests that nitrosylation of GAPDH mediates
both behavioral and neurotoxic doses of cocaine significantly.
Effects of CGP3466B on Behavioral Effects of Cocaine
We sought pharmacologic means to interrupt the cocaine-NO-
GAPDH signaling system in intact animals. The monoamine
oxidase inhibitor deprenyl is known to be neuroprotective (The
Parkinson Study Group, 1989; Hara et al., 2006; Sagot et al.,
2000; Waldmeier et al., 2000). Derivatives of deprenyl, such as
CGP3466B (Figure 3A), lack monoamine oxidase inhibitory
activity but retain neuroprotective effects (Hara et al., 2006).
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Figure 2. Effect of GAPDH or C150S GAPDH
on Behavioral and Neurotoxic Actions of
Cocaine
(A) Confocal microscopic analysis of the intra-
striatal injection of lentiviral particles of HA-
GAPDH and HA-C150S GAPDH in mice brain. (B)
Western blot analysis to detect overexpression of
HA-GAPDH and HA-C150S GAPDH in brain.
(C) Level of nitrosylation of GAPDH (SNO-GAPDH)
in striatum of mice receiving single injections of
cocaine (5–30 mg/kg). (D) Level of nitrosylation
of GAPDH (SNO-GAPDH) in striatum of mice
receiving cocaine (30–50 mg/kg for 5 days). (E and
F) Levels of c-fos (E) and CREB binding to c-fos
promoter (F) were measured in mice over-
expressing HA-GAPDH or HA-C150S GAPDH in
striatum. (G and H) PUMA protein level (G) and
p53 binding to PUMA promoter (H) weremeasured
in mice overexpressing GAPDH or GAPDH-C150S
in striatum. *p < 0.01, n = 3, one-way ANOVA,
mean ± SEM.
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SNO-GAPDH Is Key to Cocaine BehaviorCGP3466B prevents the nitrosylation of GAPDH with extraordi-
nary potency, acting in subnanomolar concentrations, with
resultant inhibition of GAPDH binding to Siah1 and nuclear trans-
location of GAPDH. Behavioral-stimulant doses of cocaine
(5–30 mg/kg) increase GAPDH nitrosylation in the corpus stria-
tum—the site of highest dopamine levels in the brain—in
a dose-dependent fashion (Figure 3B). Administration of
0.15mg/kg CGP3466B almost completely blocks the stimulation
of GAPDH nitrosylation in striatum elicited by cocaine (Fig-
ure S2A). CGP3466B also prevents the cocaine-elicited nuclear
translocation of GAPDH (Figure 3C).
Behavorial actions of cocaine are thought to involve
augmented synaptic actions of dopamine upon D1 receptors
and are typically blocked by the D1 antagonist SCH23390
(Noda and Nabeshima, 2004). Stimulation of GAPDH nitrosyla-
tion both by stimulant (Figure S2B) and neurotoxic (Figure S2C)
cocaine regimens is blocked by SCH23390 administration.
Thus, the NO-GAPDH signaling pathway, like behavioral influ-
ences of cocaine, is mediated by dopamine signaling through
D1 receptors.
With physiologic stimuli, such as the neurotrophic factors,
BDNF and NGF, the nuclear complex of nitrosylated GAPDHNeuron 78, 623–linked to Siah1 and the histone methyl-
ating enzymeSUV39H1 triggers degrada-
tion of SUV39H1 via the ubiquitin E3
ligase activity of Siah1 (Sen and Snyder,
2011). This facilitates enhanced expres-
sion of CREB regulated genes such as
c-fos. Behavioral-stimulant doses of
cocaine enhance nuclear degradation of
SUV39H1 (Figure 3D), with attendant
decreasedhistonemethylation (Figure3E)
and increased transcriptional activation
of CREB (Figure 3F) as well as augmented
expression of c-fos (Figure 3G). Adminis-
tration of CGP3466B blocks degradation
of SUV39H1 and stimulation of c-fosexpression (Figures 3D–3G). CGP3466B has no adverse effects
on central or peripheral movement (Figure S3A) or body weight
(Figure S3B) of mice.
We investigatedwhether the NO-GAPDH-CREB systemmedi-
ates behavioral-stimulant effects of cocaine. CGP3466B was
administered at 0.15mg/kg IP once a day for 5 dayswith cocaine
injected on the fifth day at the same time as the last dose of
CGP3466B. We monitored locomotor stimulation by cocaine in
an open field model (Figures 3H, S3C, and S3D). CGP3466B
(0.15 mg/kg) substantially reduces locomotor stimulation by
cocaine while having no effect on basal locomotor activity.
Cocaine induced locomotor stimulation is virtually abolished in
nNOS KOmice, consistent with participation by NO in cocaine’s
actions (Figure 3I). Administering CGP3466B to nNOS knockout
mice treated with cocaine does not further decrease locomotor
stimulation, implicating nitrosylation of GAPDH in the behavioral
responses (Figure 3I). To evaluate behavioral preference for
cocaine, we employed the conditioned place preference para-
digm, with cocaine preference reduced by CGP3466B treatment
(Figure 3J). In this experiment, mice received CGP3466B during
the preconditioning stage of the test. When mice were condi-
tioned to the chamber in the absence of CGP3466B, treatment630, May 22, 2013 ª2013 Elsevier Inc. 625
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Figure 3. CGP3466B Prevents Behavioral Actions of Cocaine
(A) Structure of CGP3466B. (B–C) CGP3466B decreases nitrosylation level of GAPDH (B) and nuclear translocation of GAPDH (C) in striatum of cocaine-treated
mice. (D and E) CGP3466B prevented cocaine-elicited degradation of SUV349H1 (D) andH3K9 trimethylation (E) in striatum. (F andG) Analysis of CREBbinding to
c-fos promoter (F) and c-fos and PUMA levels (G) inmice receiving cocainewith orwithout CGP3466B. (H) Locomotor sensitization ofmicemonitored in open field
test upon treatment with cocaine and CGP3466B. #p < 0.05, n = 10–12, two-way ANOVA, mean ± SEM. (I) Locomotor sensitization of wild-type versus nNOS
knockoutmice upon treatmentwith cocaine andCGP3466B,monitored via open-field test. #p<0.05, n=7–9, two-wayANOVA,mean±SEM. (J) Conditionedplace
preference performance in mice receiving cocaine with or without CGP3466B. #p < 0.05, n = 10–12, two-way ANOVA, mean ± SEM. See also Figures S2 and S3.
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Figure 4. Effect of Monoamine Oxidase-B
(MAO-B) Inhibitors on Cocaine-Induced
Locomotor Sensitization of Mice
(A) Analysis of nitrosylation of GAPDH in primary
cortical neuronal cells treated with the MAO-B in-
hibitors deprenyl, rasagiline, lazabemide, or pargy-
line. (B) Treatment with deprenyl, rasagiline, laz-
abemide, or pargyline has no effect on cell survival
of primary cortical neurons. (C–F) Analysis of loco-
motor sensitization by open-field test upon treat-
ment with deprenyl (C), rasagiline (D), pargyline (E),
or lazabemide (F)with orwithout cocaine. #p < 0.05,
n=10–12, two-wayANOVA,mean±SEM. (GandH)
Total beam breaks were measured in mice treated
with cocainealoneorwith cocaineanddeprenyl (G),
rasagiline, lazabemide or pargyline (H). *p < 0.01,
n = 10–12, one-way ANOVA, mean ± SEM.
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SNO-GAPDH Is Key to Cocaine Behaviorwith single dose of CGP3466B only on the day of testing failed to
alter conditional place preference (Figure S1D).
Effects of MAO-B Inhibitors on Behavioral Actions of
Cocaine
As reported earlier (Hara et al., 2006), the MAO-B inhibitor dep-
renyl, like CGP3466B, potently inhibits GAPDH nitrosylation both
in vitro and in the brains of mice treated with the neurotoxic
agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In
cortical cultures, 2 nM deprenyl, like CGP3466B, prevents
cocaine-induced nitrosylation of GAPDH (Figure 4A). Other
monoamine oxidase inhibitors such as rasagiline, lazabemide,
and pargyline do not prevent GAPDHnitrosylation. None of these
MAO-B inhibitors effects cell death in primary cortical neurons
(Figure 4B). We wondered whether deprenyl, by inhibiting
GAPDH nitrosylation, would, like CGP3466B, decrease behav-
ioral effects of cocaine (Figure 4C). However, monoamine oxi-Neuron 78, 623–dase inhibitors prevent the destruction
of dopamine, and of themselves, elicit
locomotor stimulation (Figures 4D–4F).
To discriminate the NO-GAPDH actions
from the effects of monoamine oxidase
inhibition, we compared locomotor influ-
ences of deprenyl with the other mono-
amine oxidase inhibitors (Figures 4G and
4H). Deprenyl significantly decreases
cocaine’s locomotor activation, though
to a lesser extent than CGP3466B. By
contrast, rasagiline, pargyline, and laza-
bemide, when combined with cocaine,
elicit greater locomotor stimulation than
cocaine alone. Thus, deprenyl, as well
as CGP3466B, appears to reduce loco-
motor stimulant effects of cocaine by its
inhibition of GAPDH nitrosylation.
Effects of CGP3466B on Neurotoxic
Effects of Cocaine
These experiments establish that the
NO-GAPDH signaling pathway mediatesbehavioral-stimulant effects of cocaine. We wondered whether
this cascade also participates in neurotoxic influences of
cocaine. Accordingly, we explored actions of higher doses of
cocaine (30–50 mg/kg) administered daily for 5 days with or
without CGP3466B. These higher doses of cocaine elicit robust
nitrosylation of GAPDH in the striatum, effects abolished by
CGP3466B (Figure 5A). Similarly, nuclear translocation of
GAPDH at these doses of cocaine is prevented by CGP3466B
(Figure 5B).
Earlier, we reported that cytotoxic insults, via the NO-GAPDH
pathway, lead to binding of GAPDH to the protein acetylating
enzyme p300, which in turn acetylates GAPDH and activates
the transcriptional activity of p53, resulting in induction of
PUMA (Sen et al., 2008). Neurotoxic doses of cocaine augment
binding of p300-GAPDH and acetylation of both GAPDH and
p53 in the striatum of intact animals (Figures 5C and S4A). Acti-
vation of p53 leads to increases in p53 binding to the PUMA630, May 22, 2013 ª2013 Elsevier Inc. 627
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Figure 5. CGP3466B Prevents Neurotoxic
Effects of Cocaine In Vivo
(A and B) Nitrosylation levels of GAPDH (A) and
nuclear translocation of GAPDH (B) in striatum
were decreased in mice treated with cocaine and
CGP3466B compared to cocaine treated mice. (C)
Acetylation of GAPDH and p53, as well as p300-
GAPDH association in mice treated with cocaine
with or without treatment by CGP3466B. (D and E)
Analysis of p53 binding to PUMA promoter (D) and
c-fos and PUMA levels (E) in mice treated with
cocaine with or without CGP3466B. *p < 0.01, n =
3, one-way ANOVA, mean ± SEM. (F) Analysis of
cell death by TUNEL assay in striatum induced by
cocaine with or without chronic treatment with
CGP3466B in mice. *p < 0.01, n = 9, one-way
ANOVA, mean ± SEM. (G) Balance and coordina-
tion of motor activity evaluated by rotarod analysis
test in mice receiving cocaine with or without
CGP3466B. #p < 0.05, ##p < 0.01, n = 9, two-way
ANOVA, mean ± SEM. See also Figure S4.
Neuron
SNO-GAPDH Is Key to Cocaine Behaviorpromoter (Figure 5D) and augmentation of PUMA levels (Fig-
ure 5E). However, in contrast to low doses of cocaine, which
activate c-fos but not PUMA, at high cocaine doses c-fos is un-
detectable, while PUMA expression is increased. CGP3466B
blocks activation of p53 (Figures 5C and 5D) and induction of
PUMA level (Figure 5E).
To evaluate cocaine neurotoxicity, we monitored apoptosis
utilizing the TUNEL procedure (Figure 5F). Cellular apoptosis is
increased by cocaine at 30 mg/kg with substantially greater
effects at 50 mg/kg. Treatment with CGP3466B markedly
reduces apoptosis.628 Neuron 78, 623–630, May 22, 2013 ª2013 Elsevier Inc.As a behavioral index of neurotoxic
insults of cocaine, we examined motor
coordination in the rotarod test (Fig-
ure 5G). At 50 mg/kg cocaine disrupts
performance, substantially lowering the
latency for falling off the rod. Cotreatment
with CGP3466B markedly improves per-
formance, increasing latency 2.5- to
3-fold. By contrast, the MAO-B inhibitors
deprenyl, rasagiline, pargyline, and laza-
bemide do not rescue cocaine induced
cell death (Figure S4B) and do not
improve rotarod performance (Fig-
ure S4C). Moreover, under basal condi-
tions in the absence of cocaine, these
drugs do not affect rotarod performance.
The failure of deprenyl to elicit protective
effects in these experimental conditions
may reflect its monoamine oxidase inhib-
itory actions potentiating the disruptive
influences of cocaine.
DISCUSSION
In summary, our study establishes that
cocaine signals by stimulating the NO-GAPDH signaling cascade involving nuclear translocation of
GAPDH to alter transcriptional events. At lower, behavioral-
stimulant doses cocaine predominantly signals through CREB,
thence the c-fos promoter, activating transcription of genes
such as BDNF and Arc. By contrast, high, neurotoxic doses pre-
ponderantly elicit p53 mediated transcription of prodeath genes
such as PUMA and Bax. Earlier, we differentiated molecular
mechanisms for cytotoxic versus neurotrophic signaling by the
NO-GAPDH system (Sen et al., 2008; Sen and Snyder, 2011).
Following cytotoxic insults nuclear GAPDH activates acetylation
by p300/CBP of p53 leading to prodeath gene stimulation (Sen
Neuron
SNO-GAPDH Is Key to Cocaine Behavioret al., 2008). On the other hand, physiologic stimulation by
neurotrophic agents such as BDNF and NGF elicits nuclear
association of GAPDH with Siah1 in a complex with the histone
methylating enzyme SUV39H1 (Sen and Snyder, 2011). In this
complex Siah1, via its ubiquitin E3 ligase activity, elicits degrada-
tion of SUV39H1. The resultant decreasedmethylation of histone
H3K9 leads to augmented acetylation of this histone and
increased transcription by CREB leading to enhanced neuronal
outgrowth (Sen and Snyder, 2011). We presume that the behav-
ioral-stimulant and neurotoxic actions of cocaine reflect the
signaling systems linked to CREB and p53, respectively.
We employed CGP3466B as a tool to inhibit GAPDH nitro-
sylation potently and selectively and thereby disrupt the
signaling cascade. CGP3466B prevents transcriptional sig-
naling of cocaine and reverses both the behavioral stimuli
and the neurotoxic actions of cocaine. Deprenyl, which like
CGP3466B, blocks GAPDH nitrosylation, also reduces behav-
ioral-stimulant effects of cocaine. Its actions contrast with those
of other monoamine oxidase inhibitors that do not affect
GAPDH nitrosylation and which, instead, augment cocaine’s
stimulant influences.
Our studies may have therapeutic implications. In this context
it is notable that pretreatment with CGP3466B reduces condi-
tioned placed preference, a measure of cocaine seeking
behavior. Individuals ingesting high doses of cocaine often expe-
rience life-threatening brain damage. The ability of CGP3466B to
decrease the neurotoxic effects of cocaine implies that drugs
such as CGP3466B may be of value in treating cocaine over-
dose. CGP3466B and related drugs display neuroprotective
actions in numerous animal models including Parkinson’s dis-
ease (Hara et al., 2006; LeWitt, 2004; Olanow et al., 2006; Wald-
meier et al., 2000) motorneuron disease (Sagot et al., 2000),
muscular dystrophy (Erb et al., 2009; Meinen et al., 2011), and
amyotrophic lateral sclerosis (Leigh et al., 2004; Miller et al.,
2007).EXPERIMENTAL PROCEDURES
Unless otherwise noted, all data are representative of three individual
experiments.
Drugs
Cocaine HCl (Sigma-Aldrich) was dissolved in physiological saline. CGP3466B
was obtained from Tocris Bioscience and dissolved to 10 mM in water and
100 mM in DMSO (vehicle). Deprenyl (soluble in PBS), Rasagiline (soluble in
PBS), Lazabemide (soluble in DMSO), SCH32290 (soluble in PBS), and
Pargyline (soluble in PBS) were obtained from Sigma. Antibodies purchased
from commercial: c-fos (Santa Cruz, 1:150 dilution), Arc (Santa Cruz, 1:250
dilution), and PUMA (Santa Cruz, 1:250 dilution), CREB (Santa Cruz, 2 mg
per 100–500 mg of total protein), and p53 (Santa Cruz, 2 mg per 100–500 mg
of total protein).
Sample Preparation from Cocaine-Injected Mice
C57BL/6mice and nNOS knockout (Jackson) mice were injected once per day
(intraperitoneally [i.p.]) with saline or cocaine (0–50 mg/kg) before rapid isola-
tion of striatum 1 hr after injection.. Striatum lysates were used to measure
nitrosylation of GAPDH by biotin switch assay. Striatum lysates were also
used to do western blot hybridization to measure c-fos, Arc, PUMA levels,
and ChIP assay to measure CREB and p53 binding to c-fos and PUMA pro-
moter respectively.Behavioral Testing
Mice
Male wild-type mice with C57BL/6 genetic background from Jackson labora-
tories at 10 weeks of age were used for all behavioral testing. All animals were
handled according to the Johns Hopkins University School of Medicine Animal
Care and Use guidelines.
Open-Field Test
Open-field assessments were conducted as described (Levine et al., 2011;
Maze et al., 2010) with brief modifications. The open field is a square arena
with the dimensions 47 cm 3 47 cm with a 38.1 cm high clear plastic wall.
Activity chambers were computer interfaced for data sampling. Sixteen
infrared photobeams in each direction (16 3 16), 2.77 cm spacing, were
used to record movement. The San Diego PAS software recorded the total
number of beam breaks, as well as the beam break’s location in the center
and peripheral areas.
Mice were divided in 5 groups (n = 10–12 each). Each group of mice were
injected (i.p.) with either CGP3466B or the MAO-B inhibitors deprenyl, rasagi-
line, lazabemide, and pargyline for 5 days. Mice were allowed to acclimate to
the apparatus for 1 hr. After 60 min, mice received saline or cocaine (30 mg /kg
of cocaine i.p.), and were returned to the open-field apparatus for a sub-
sequent 75 min in which their activity was recorded. All data was measured
in 5min intervals and aggregated as necessary. Beam breaks or distance trav-
eled for 20 min following cocaine/saline intraperitoneal injection after the first
stage of testing were used to determine immediate peak locomotor response
from cocaine injection. In between testing of mice, the arena was wiped with
Vimoba cleaning solution.Mice were tested at the same time every day in order
to minimize any variation due to circadian rhythm changes.
Rotarod Performance
The test was performed as described previously (Xi et al., 2011) with minor
modifications. A four-station mouse rotarod device (AccuScan Instruments)
was used to study the effects of CGP3466B, Deprenyl, Rasagiline, Lazabe-
mide and Pargyline on cocaine induced operant locomotion in mice. The
speed of rotation of the rotarod was increased from 4 to 32 rpm over 7 min.
Mice were divided into 5 groups (n = 8). For 5 days prior to testing mice
received one dose of deprenyl (0.25 mg/kg), rasagiline (2.5 mg/kg), pargyline
(50 mg/kg), lazabemide (50 mg/kg), or saline followed by a high dose of
cocaine (50 mg/kg). Mice were placed on the rotarod at a starting speed of
4 rpm, and the speed of the rotarod was increased to 32 rpm over the course
of 7 min. This was repeated for a total of three trials in a day, and the latency at
which the mice fell off the rotarod was recorded. Mice were tested at the same
time every day in order to minimize any variation due to circadian rhythm
changes.
Conditioned Place Preference
The test was performed as described previously (Levine et al., 2011; Maze
et al., 2010; Xi et al., 2011) with minor modifications. Two groups of wild-type
mice were used to study the effect of CGP 3466B (0.15 mg/kg) on cocaine-
(7 mg/kg) induced conditioned place preference or aversion. A three-chamber
place preference apparatus was used. This apparatus consisted of two large
side compartments and one small central compartment, which separated the
large compartments. Two of the large compartments had different visual and
tactile cues. One of the large compartments contained a greenwiremesh floor.
The second large compartment contained a cream-colored rubber floor. The
small central compartment had a smooth clear Plexiglas floor. A white opaque
wall encircled the apparatus in order to block out any other visual cues in the
behavioral testing area.
Wild mice were divided into two groups. During the preconditioning phase
(day 1), mice were placed in the small central compartment and were allowed
to freely explore the entire apparatus for 15 min. Experimental software (Any-
Maze Video Tracking System v. 4.72) measured the amount of time each
mouse spent in each of the three compartments. Mice that did not show a
strong preference for either of the large chambers on day 1 were advanced
to the next stage of testing.
For the next 10 days (days 2–11), mice entered the conditioning stage of
testing with one session per day. On days 2, 4, 6, 8, and 10, one of the groups
received an injection of saline and were then confined into the cream-colored
rubber floor compartment for 15 min immediately following injection. The sec-
ond group received an injection of CGP 3466B (0.15 mg/kg) exactly 2 hr priorNeuron 78, 623–630, May 22, 2013 ª2013 Elsevier Inc. 629
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SNO-GAPDH Is Key to Cocaine Behaviorto testing and then received a second injection of saline before being confined
to the same cream-colored rubber floor compartment for 15 min. The
compartment was cleaned with Vimoba in between mice. On days 3, 5, 7, 9,
and 11, this same protocol was followed, substituting the saline injection
with cocaine (7 mg/kg) before both groups were confined to the green-mesh
floor chamber for 15 min. The treatment group continued to receive an intra-
peritoneal injection of CGP3466B (0.15 mg/kg) exactly 2 hr before receiving
the cocaine conditioning injection. Only one session of conditioning was con-
ducted each day. On the probe trial day (24 hr after the last conditioning ses-
sion), mice were given an injection of saline then were allowed to freely explore
the three compartments for 15min the time spent in each of the compartments
was recorded by computer software. CPP score was calculated as time spent
in cocaine chamber minus the time spent in saline/CGP3466B treated
chamber.
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